Insmed Stock Plummets on Sinus Drug Trial Failure; Analyst Weighs In

Insmed's Sinus Drug Trial Disappointment

• 📉 Insmed shares experienced their worst day since May 2021, dropping 16% after discontinuing development of a chronic sinusitis drug.
• ⚠️ The drug failed to meet primary and secondary endpoints in its trial, despite having prior FDA clearance for a chronic lung disease.

Impact on Financial Models

• 📊 Analysts, including Mizuho's, had factored in significant sales for the sinus drug, estimated between $3 to $5 billion.
• 💡 The removal of this drug from models necessitates a reassessment of Insmed's valuation, with a focus on other key assets.

Brenzo's Future Potential

• 💰 Even without the sinus indication, Brenzo is still projected to be a $10 billion drug, according to company statements and street estimates.
• 🎯 The stock's current valuation of 40 billion with four times sales is considered potentially reasonable if Brenzo achieves its projected peak sales.

Pipeline and Acquisitions

• 🔬 Insmed is exploring other indications for Brenzo, including a rare skin disease (HS UCB), though the probability of success is estimated below 30% with potential for about $1 billion in sales.
• ❓ The recent acquisition of an antibody drug was unexpected and announced on the same day as the trial discontinuation, leaving the street with limited analysis and no consensus.

Investment Opportunity

• ✅ Despite the setback, the current stock price presents an opportunity, with numbers becoming less egregious after the pullback.
• 🚀 While a repeat of the previous year's 140% growth is unlikely, a 20-30% return may be achievable, suggesting it could be a trade rather than a long-term monster year.